Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar scrubs62074 (86.05) Submitted: 2/13/2013 11:17:30 AM : Outperform Start Price: $2.15 PPHM Score: -56.52

High Volume Breakout on 02/13/13

Featured Broker Partners


Advertisement